Loading
PSMB1 (Proteasome subunit beta type-1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.63, genetic association 0.00, clinical 0.99).
In plain words · PSMB1 (Proteasome subunit beta type-1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
PSMB1 (Proteasome subunit beta type-1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins.
No product in this corpus aims at PSMB1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists PSMB1 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PSMB1: RNA low tissue specificity; high antibody staining in 17 normal tissues; highest cancer staining endometrial cancer (11 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PSMB1 tissue; Open Targets ENSG00000008018 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Lee L.W. et al, Biochim. Biophys. Acta, 1990, "Relationships among the subunits of the high molecular weight proteinase, macropain (proteasome)". Source.
Sources: HGNC HGNC:9537 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P20618 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000008018 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: plasma cell myeloma 0.61, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
Non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Location: Cytoplasm; Nucleus (UniProt). Locus 6q27 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Bone marrow, Breast, Caudate, Cerebellum, Cerebral cortex, Cervix, Epididymis, Esophagus.
Medium only: carcinoid, prostate cancer.
HPA PSMB1 tissue · HPA PSMB1 pathology · HPA protein class: Essential proteins, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PSMB1" OR ABSTRACT:"PSMB1" OR TITLE:"proteasome 20S subunit beta 1" OR ABSTRACT:"proteasome 20S subunit beta 1" OR TITLE:"Proteasome subunit beta type-1" OR ABSTRACT:"Proteasome subunit beta type-1" OR TITLE:"PMSB1" OR ABSTRACT:"PMSB1" OR TITLE:"HC5" OR ABSTRACT:"HC5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PSMB1, not a curated reading list.